Canada cancels massive Covid vaccine agreement with China as Xi & co fail to deliver

In a massive setback to China, Canian Government on Saturday cancelled its multi-million dollar development agreement with communist country's leing vaccine candidate due to a 'delay in shipment of drugs.' Issuing an official statement, Chinese National Research Council said that opportunity with Cana was 'w over', due to delay in shipment of vaccine doss to rth American country ding that NRC would w focus on 'or COVID-19 priorities.'

" agreement between NRC and CanSi h been reviewed prior to signature by CanSi's collaborators in Chinese Government - Beijing Institute of Techlogy and Ministry of Science and Techlogy - who h provided funding to CanSi," said China's National Research Council. 

"Due to delay in shipment of CanSi Covid-19 vaccine candidate doses to Cana and as CanSi has w completed phase 1 and phase 2 clinical trials elsewhere, this specific opportunity is over and NRC is focusing its team and facilities on or Covid-19 priorities," council said.

Re: China Grants First COVID-19 Vaccine Patent To CanSi Biologics' 'experimental Vaccine'

Re: CanSi's Vaccine For COVID-19 Gets d For Military Use In China

Strained ties between Cana & China?

Speculations have however arisen on wher Cana's move was a larger snub to China over its arbitrary detainment of two Canian nationals which was followed by its decision to halt billions of dollars of agricultural imports. relations between two countries have been on a slow decline following arrest of Meng Wanzhou, daughter of founder of Chinese tech giant Huawei on an extrition request of United States back in 2018. 

China's state-sponsored media South China Morning Post reported that reason for Cana's decision to scrap deal remained 'unclear' ding that it was t certain on wher it h anything to do with political tensions between two countries. CanSi's 5-nCoV h been approved by Canian government for human testing in country.  

"We are actively pursuing discussions with or partners to collaborate on or vaccine candidates and will anunce se collaborations as y are confirmed," said China's National Research Council. 

Progress on CanSi's vaccine

On August 18, China h granted its first COVID-19 vaccine patent to CanSi Biologics' vaccine with Chinese media reporting that it h found evirus vector vaccine candidate to found to be 'successful in triggering an immune response' in first and second sts of clinical trials.

According to Chinese media, vaccine is yet to complete third and largest phase of trials before gaining market approval, however, animal studies have demonstrated vaccine's ability to reduce viral amounts in lungs reby inducing immunity.   vaccine candidate has been jointly developed by CanSi Biologics and Beijing Institute of Biotechlogy in Acemy of Military Medical Sciences.

Re: Russia To Conduct Clinical Trials Of Its Controversial Coronavirus Vaccine In Saudi Arabia

Re: Mexico Needs 200 Million Coronavirus Vaccine Doses, To Start Shots In April 2021